@article{Kengo Takeuchi_Manabu Soda_Yuki Togashi_Yasunori Ota_Yasunobu Sekiguchi_Satoko Hatano_Reimi Asaka_Masaaki Noguchi_Hiroyuki Mano_2011, place={Pavia, Italy}, title={Identification of a novel fusion, SQSTM1-ALK, in ALK-positive large B-cell lymphoma}, volume={96}, url={https://haematologica.org/article/view/5911}, DOI={10.3324/haematol.2010.033514}, abstractNote={ALK-positive large B-cell lymphoma is a rare subtype of lymphoma, and most cases follow an aggressive clinical course with a poor prognosis. We examined an ALK-positive large B-cell lymphoma case showing an anti-ALK immunohistochemistry pattern distinct from those of 2 known ALK fusions, CLTC-ALK and NPM-ALK, for the presence of a novel ALK fusion; this led to the identification of SQSTM1-ALK. SQSTM1 is an ubiquitin binding protein that is associated with oxidative stress, cell signaling, and autophagy. We showed transforming activities of SQSTM1-ALK with a focus formation assay and an <em>in vivo</em&gt; tumorigenicity assay using 3T3 fibroblasts infected with a recombinant retrovirus encoding SQSTM1-ALK. ALK-inhibitor therapies are promising for treating ALK-positive large B-cell lymphoma, especially for refractory cases. SQSTM1-ALK may be a rare fusion, but our data provide novel biological insights and serve as a key for the accurate diagnosis of this rare lymphoma.}, number={3}, journal={Haematologica}, author={Kengo Takeuchi and Manabu Soda and Yuki Togashi and Yasunori Ota and Yasunobu Sekiguchi and Satoko Hatano and Reimi Asaka and Masaaki Noguchi and Hiroyuki Mano}, year={2011}, month={Feb.}, pages={464-467} }